In-depth immune monitoring, performed by immunologists. CellCarta's scientific expertise delivers the data you need across preclinical and clinical programs.
For studies that require in-depth analysis of the immune landscape, our state-of-the-art platforms enable high-quality data generation. CellCarta's immunology services are built to serve pharmaceutical and biotech partners across the full scope of immune monitoring.
Working within CAP-accredited, CLIA-certified laboratories, our team of scientific experts develops, validates and deploys assays that generate reliable, reproducible data across broad immunology and inflammation therapeutic programs.
Don’t see your indication? Contact us about custom solutions.
Contact Us
Measure immune dysregulation and mechanisms of action in conditions like lupus and MS.
Immune profiling of clinical trial cancer patients receiving CAR or TCE.
Evaluate immune responses to infectious disease treatments and prophylactic vaccines.
Identify and screen for changes in immune gene expression to confirm candidate biomarkers.
Assess vaccine efficacy by cytokine measurements, using cutting edge platforms.
For rich phenotypic and functional insights regarding your immune cell subsets , our team can profile a variety of immune subsets and markers using multiparametric flow cytometry, generating data that reflects how the immune system responds to therapeutics.
For cytokine, chemokine, and soluble immune biomarker quantification, CellCarta provide sensitivity and precision across our validated immunoassay platforms: Olink®, MSD®, Ella™, and ELISA.
For studies that require large-scale unbiased immune biomarker discovery and quantification, we can perform high-resolution mass spectrometry via MRM and PRM, enabling a more comprehensive view of the immune landscape from a small starting sample volume.
CellCarta can develop and validate custom fit-for-purpose assays. We offer assay design for any clinical endpoint across our major platforms, including flow cytometry, mass spectrometry, ELISpot, and more.
Assays are validated to meet regulatory submission and clinical decision-making requirements, including GLP/GCLP qualification.
CellCarta supports early drug discovery through multi-omics integration, connecting preclinical findings to clinical-stage decision points. This includes:
Every service is delivered with rigorous quality assurance. Our laboratories operate under GCLP-compliant systems with CAP accreditation and CLIA certifications.
We follow international guidelines and perform thorough assay validation, so you can trust the data generated for clinical decision-making and regulatory submissions.
For rich phenotypic and functional insights regarding your immune cell subsets , our team can profile a variety of immune subsets and markers using multiparametric flow cytometry, generating data that reflects how the immune system responds to therapeutics.
For cytokine, chemokine, and soluble immune biomarker quantification, CellCarta provide sensitivity and precision across our validated immunoassay platforms: Olink®, MSD®, Ella™, and ELISA.
For studies that require large-scale unbiased immune biomarker discovery and quantification, we can perform high-resolution mass spectrometry via MRM and PRM, enabling a more comprehensive view of the immune landscape from a small starting sample volume.
CellCarta can develop and validate custom fit-for-purpose assays. We offer assay design for any clinical endpoint across our major platforms, including flow cytometry, mass spectrometry, ELISpot, and more.
Assays are validated to meet regulatory submission and clinical decision-making requirements, including GLP/GCLP qualification.
CellCarta supports early drug discovery through multi-omics integration, connecting preclinical findings to clinical-stage decision points. This includes:
Every service is delivered with rigorous quality assurance. Our laboratories operate under GCLP-compliant systems with CAP accreditation and CLIA certifications.
We follow international guidelines and perform thorough assay validation, so you can trust the data generated for clinical decision-making and regulatory submissions.
Discover the technologies that empower our services in the immunology therapeutic area, enabling comprehensive immune profiling solutions.
Our flow cytometry services deliver qualitative and quantitative analysis of immune cells at the single-cell level. Equipped with multiparametric flow instruments, including the spectral Cytek Aurora platform that detects up to 40 parameters per cell, our laboratories support deep immune profiling from a single run.
We can quantify soluble immune biomarkers with four major platforms: Olink® for high-multiplex protein profiling; MSD® for targeted cytokine, chemokine, and growth factor panels; Ella™ for automated, rapid-turnaround analysis; and ELISA for single-analyte specificity.
We have proficiency in using ELISpot and FluoroSpot for in-depth immune profiling. For example, ELISpot and FluoroSpot enumerate antigen-specific T cells at the single-cell level, including IFN-γ producing T cells in viral infection and vaccine immunogenicity studies.
Case Study
CellCarta validated the TBNK + CD20 enumeration assay as a highly sensitive method for peripheral B-cell monitoring in B-cell-depleting therapy (BCDT) clinical trials. This approach is a useful tool for the assessment and prediction of BCDT efficacy in autoimmune diseases and more.
Case Study
CellCarta performed a comparative analysis of the immune profiles of carcinoma samples when evaluated by the AI-powered Lunit SCOPE IO platform or manually by pathologists. Insights gained from this analysis serve to improve the robustness of both methods for immune phenotype investigations.
Immunology expertise that spans from assay development to data delivery.
Custom Assay Development
Rich Scientific Expertise
Global Support
Multi-Modal Integration
Regulatory Compliance
Blog
Posters
CellCarta offers a comprehensive range of immune monitoring assays including multiparametric flow cytometry, IHC, digital pathology, immunoassays across four major platforms (Olink®, MSD®, Ella™, and ELISA), and ELISpot/FluoroSpot for antigen-specific T cell enumeration. Fit-for-purpose assays can be developed for your program's exploratory, primary, and secondary endpoints.
CellCarta's scientists develop custom assays for targets across all components of the immune system, including rare immune events where standard panels are insufficient. The scientific team collaborates with sponsors from study design through to data analysis, providing guidance on methodology and validation strategy at every stage. All custom assays are validated under GLP/GCLP regulations from the beginning.
CellCarta's global laboratory network spans Canada, the USA, Belgium, Australia, and China, supporting multinational clinical trials with the capacity to process large patient cohorts across geographies. Our globally harmonized SOPs minimize inter-site variability, and CAP accreditation with CLIA certification applies across all network sites. However, local expertise on regulation and policies ensures tailored support for your study. This infrastructure means sponsors working across multiple clinical sites receive consistent, regulatory-ready data regardless of where samples originate.
Yes. Flow cytometry, multiplex immunoassays, ELISpot/FluoroSpot, genomics, and histopathology can be incorporated into a single workflow using our multi-modal expertise. We also provide bioinformatics support, including our CellEngine® software, which enables integrated multi-omic data analysis. This structure supports programs where mechanistic understanding requires correlating immune cell phenotype with gene expression, protein biomarker profiles, and tissue pathology.
